In response to the soluble ligand limitation, a series of new hinge CAR variants (truncated, deletion, flexible and ‘CD8 hinge & TM’) were evaluated, and the CD8 hinge and TM variants were found to have enhanced anti‐tumour activity and better expansion capacity in vitro and in vivo compared to natural 41BB‐based CAR‐T cells. The gene discussed is CD8A; the disease is neoplasm.